Shares of Iterum Therapeutics plc (NASDAQ:NRBO) have been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.

Analysts have set a 12 month consensus target price of $25.00 for the company and are anticipating that the company will post ($0.27) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Iterum Therapeutics an industry rank of 51 out of 254 based on the ratings given to related companies.

NRBO has been the subject of a number of analyst reports. ValuEngine raised shares of Iterum Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 20th. HC Wainwright initiated coverage on shares of Iterum Therapeutics in a research report on Monday, June 15th. They issued a “buy” rating and a $20.00 target price for the company. Finally, Zacks Investment Research cut shares of Iterum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 3rd.

An institutional investor recently bought a new position in Iterum Therapeutics stock. Hayden Royal LLC bought a new position in shares of Iterum Therapeutics plc (NASDAQ:NRBO) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 34,176 shares of the company’s stock, valued at approximately $645,000. Hayden Royal LLC owned about 5.74% of Iterum Therapeutics at the end of the most recent reporting period. 1.44% of the stock is owned by institutional investors.

NASDAQ:NRBO traded down $0.77 on Friday, hitting $9.08. 543,089 shares of the stock were exchanged, compared to its average volume of 50,849. The firm has a market capitalization of $149.16 million, a PE ratio of -2.23 and a beta of 0.81. Iterum Therapeutics has a 52 week low of $5.95 and a 52 week high of $30.00. The business has a 50-day moving average of $12.40.

Iterum Therapeutics (NASDAQ:NRBO) last issued its quarterly earnings data on Wednesday, May 20th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.20). Equities research analysts expect that Iterum Therapeutics will post -0.74 EPS for the current fiscal year.

Iterum Therapeutics Company Profile

NeuroBo Pharmaceuticals, Inc provides novel therapies for diabetic neuropathic pain and central nervous system diseases. NeuroBo Pharmaceuticals, Inc was founded in 2017 and is based in Boston, Massachusetts.

Recommended Story: When can a hold rating present a buying opportunity?

Get a free copy of the Zacks research report on Iterum Therapeutics (NRBO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with's FREE daily email newsletter.